 Orchard Therapeutics plc NASDAQ: ORTX and Pharming Group NV NASDAQ: PHAR have collaborated to research, develop, manufacture and commercialize OTL-105 for hereditary angioedema HAE. OTL-105 is an investigational autologous hematopoietic stem cell HSC gene therapy designed to increase C1 esterase inhibitor C1-INH in HAE patient serum to prevent hereditary angioedema attacks. 